Last reviewed · How we verify
Reteplase 10 U
Reteplase is a fibrinolytic enzyme that breaks down blood clots by converting plasminogen to plasmin, which degrades fibrin.
Reteplase is a fibrinolytic enzyme that breaks down blood clots by converting plasminogen to plasmin, which degrades fibrin. Used for Acute myocardial infarction (AMI) for thrombolysis.
At a glance
| Generic name | Reteplase 10 U |
|---|---|
| Also known as | Retavase |
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | Fibrinolytic agent; tissue plasminogen activator (tPA) |
| Target | Fibrin; plasminogen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Reteplase is a recombinant tissue plasminogen activator (tPA) that works by binding to fibrin in blood clots and catalyzing the conversion of plasminogen to plasmin. Plasmin then degrades the fibrin matrix that holds the clot together, leading to clot dissolution. This restores blood flow in occluded vessels, particularly in acute myocardial infarction.
Approved indications
- Acute myocardial infarction (AMI) for thrombolysis
Common side effects
- Bleeding (including intracranial hemorrhage)
- Reperfusion arrhythmias
- Hypotension
- Allergic reactions
Key clinical trials
- Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization (PHASE4)
- Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reteplase 10 U CI brief — competitive landscape report
- Reteplase 10 U updates RSS · CI watch RSS
- The University of Texas Health Science Center, Houston portfolio CI